MONTREAL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Paul Lévesque, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Fitzgerald Global Healthcare Conference 2023 being held September 26-28 in New York City.
Presentation Details | |
Date: | Wednesday, September 27, 2023 |
Time: | 8:00 - 8:30 AM EDT in Track 2 |
Location: | Intercontinental Barclay New York Hotel |
Mr. Lévesque and Mr. Philippe Dubuc, Senior Vice President and Chief Financial Officer, will also be available for 1x1 investor meetings.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and Twitter.
Contacts:
Investor Inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
438-315-6608
Last Trade: | US$2.61 |
Daily Change: | 0.02 0.77 |
Daily Volume: | 242,822 |
Market Cap: | US$120.010M |
April 09, 2025 April 08, 2025 March 12, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load